Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

NCT03721107 is registered in ClinicalTrials.gov with 4D pharma plc as lead sponsor.

NCT NCT03721107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03721107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D
Lead sponsor
4D pharma plc
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2018
Completion date
May 13, 2020
Enrollment
366 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome